Molecule based diagnosis

Hideyuki Akaza, Tomohiko Ichikawa, Takashi Tsuruo, Yasuhiro Shimada, Hisataka Moriwaki, Masaki Mori, Shinzaburo Noguchi, Seigo Nakamura, Nagahiro Saijo, Saburo Sone, Seiji Isonishi, Yasuo Ohashi, Shiro Hinotsu, Mikael von Euler, George Blackedge

Research output: Contribution to journalArticle

Abstract

Based on reviews of the concept of diagnostics and in general and in specific tumour areas it was clear that development of diagnostic procedures involving genomics will allow for much better targeted and tailored treatments in the future. This will result in better efficacy and better tolerability of cancer treatments, but will also allow for progress in prediction, diagnosis and dose selection. Large collaborative projects studying the efficacy and safety of drugs on the genome level is promising to bring important benefits to both patients and the national economy by reducing useless drug therapy. In colorectal cancer there are several genetic defects identified that can act as the target for directed therapy in the future. Expressions of tumour specific antigens open the way for immunological targeted therapies. Developments in the understanding of the genomic basis for resistance to anti-tumour therapy is promising to help targeting patients likely to respond and not develop resistance. A Japanese model is being developed to determine the relative risk of breast cancer of Japanese women. Based on this prevention therapies can be instigated. The last four years have seen the introduction of four novel targeted therapies. If this model should become a standard in the future, much stronger collaboration between academic research and pharmaceutical industry need to develop.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number1
Publication statusPublished - Jan 2004
Externally publishedYes

Fingerprint

Therapeutics
Neoplasms
Drug Industry
Neoplasm Antigens
Genomics
Colorectal Neoplasms
Genome
Breast Neoplasms
Safety
Drug Therapy
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Akaza, H., Ichikawa, T., Tsuruo, T., Shimada, Y., Moriwaki, H., Mori, M., ... Blackedge, G. (2004). Molecule based diagnosis. Gan to kagaku ryoho. Cancer & chemotherapy, 31(1), 125-133.

Molecule based diagnosis. / Akaza, Hideyuki; Ichikawa, Tomohiko; Tsuruo, Takashi; Shimada, Yasuhiro; Moriwaki, Hisataka; Mori, Masaki; Noguchi, Shinzaburo; Nakamura, Seigo; Saijo, Nagahiro; Sone, Saburo; Isonishi, Seiji; Ohashi, Yasuo; Hinotsu, Shiro; von Euler, Mikael; Blackedge, George.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 1, 01.2004, p. 125-133.

Research output: Contribution to journalArticle

Akaza, H, Ichikawa, T, Tsuruo, T, Shimada, Y, Moriwaki, H, Mori, M, Noguchi, S, Nakamura, S, Saijo, N, Sone, S, Isonishi, S, Ohashi, Y, Hinotsu, S, von Euler, M & Blackedge, G 2004, 'Molecule based diagnosis', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 31, no. 1, pp. 125-133.
Akaza H, Ichikawa T, Tsuruo T, Shimada Y, Moriwaki H, Mori M et al. Molecule based diagnosis. Gan to kagaku ryoho. Cancer & chemotherapy. 2004 Jan;31(1):125-133.
Akaza, Hideyuki ; Ichikawa, Tomohiko ; Tsuruo, Takashi ; Shimada, Yasuhiro ; Moriwaki, Hisataka ; Mori, Masaki ; Noguchi, Shinzaburo ; Nakamura, Seigo ; Saijo, Nagahiro ; Sone, Saburo ; Isonishi, Seiji ; Ohashi, Yasuo ; Hinotsu, Shiro ; von Euler, Mikael ; Blackedge, George. / Molecule based diagnosis. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 1. pp. 125-133.
@article{c100329122ef491e9266eeb50dc7b2a9,
title = "Molecule based diagnosis",
abstract = "Based on reviews of the concept of diagnostics and in general and in specific tumour areas it was clear that development of diagnostic procedures involving genomics will allow for much better targeted and tailored treatments in the future. This will result in better efficacy and better tolerability of cancer treatments, but will also allow for progress in prediction, diagnosis and dose selection. Large collaborative projects studying the efficacy and safety of drugs on the genome level is promising to bring important benefits to both patients and the national economy by reducing useless drug therapy. In colorectal cancer there are several genetic defects identified that can act as the target for directed therapy in the future. Expressions of tumour specific antigens open the way for immunological targeted therapies. Developments in the understanding of the genomic basis for resistance to anti-tumour therapy is promising to help targeting patients likely to respond and not develop resistance. A Japanese model is being developed to determine the relative risk of breast cancer of Japanese women. Based on this prevention therapies can be instigated. The last four years have seen the introduction of four novel targeted therapies. If this model should become a standard in the future, much stronger collaboration between academic research and pharmaceutical industry need to develop.",
author = "Hideyuki Akaza and Tomohiko Ichikawa and Takashi Tsuruo and Yasuhiro Shimada and Hisataka Moriwaki and Masaki Mori and Shinzaburo Noguchi and Seigo Nakamura and Nagahiro Saijo and Saburo Sone and Seiji Isonishi and Yasuo Ohashi and Shiro Hinotsu and {von Euler}, Mikael and George Blackedge",
year = "2004",
month = "1",
language = "English",
volume = "31",
pages = "125--133",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Molecule based diagnosis

AU - Akaza, Hideyuki

AU - Ichikawa, Tomohiko

AU - Tsuruo, Takashi

AU - Shimada, Yasuhiro

AU - Moriwaki, Hisataka

AU - Mori, Masaki

AU - Noguchi, Shinzaburo

AU - Nakamura, Seigo

AU - Saijo, Nagahiro

AU - Sone, Saburo

AU - Isonishi, Seiji

AU - Ohashi, Yasuo

AU - Hinotsu, Shiro

AU - von Euler, Mikael

AU - Blackedge, George

PY - 2004/1

Y1 - 2004/1

N2 - Based on reviews of the concept of diagnostics and in general and in specific tumour areas it was clear that development of diagnostic procedures involving genomics will allow for much better targeted and tailored treatments in the future. This will result in better efficacy and better tolerability of cancer treatments, but will also allow for progress in prediction, diagnosis and dose selection. Large collaborative projects studying the efficacy and safety of drugs on the genome level is promising to bring important benefits to both patients and the national economy by reducing useless drug therapy. In colorectal cancer there are several genetic defects identified that can act as the target for directed therapy in the future. Expressions of tumour specific antigens open the way for immunological targeted therapies. Developments in the understanding of the genomic basis for resistance to anti-tumour therapy is promising to help targeting patients likely to respond and not develop resistance. A Japanese model is being developed to determine the relative risk of breast cancer of Japanese women. Based on this prevention therapies can be instigated. The last four years have seen the introduction of four novel targeted therapies. If this model should become a standard in the future, much stronger collaboration between academic research and pharmaceutical industry need to develop.

AB - Based on reviews of the concept of diagnostics and in general and in specific tumour areas it was clear that development of diagnostic procedures involving genomics will allow for much better targeted and tailored treatments in the future. This will result in better efficacy and better tolerability of cancer treatments, but will also allow for progress in prediction, diagnosis and dose selection. Large collaborative projects studying the efficacy and safety of drugs on the genome level is promising to bring important benefits to both patients and the national economy by reducing useless drug therapy. In colorectal cancer there are several genetic defects identified that can act as the target for directed therapy in the future. Expressions of tumour specific antigens open the way for immunological targeted therapies. Developments in the understanding of the genomic basis for resistance to anti-tumour therapy is promising to help targeting patients likely to respond and not develop resistance. A Japanese model is being developed to determine the relative risk of breast cancer of Japanese women. Based on this prevention therapies can be instigated. The last four years have seen the introduction of four novel targeted therapies. If this model should become a standard in the future, much stronger collaboration between academic research and pharmaceutical industry need to develop.

UR - http://www.scopus.com/inward/record.url?scp=1342288800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342288800&partnerID=8YFLogxK

M3 - Article

C2 - 14750337

AN - SCOPUS:1342288800

VL - 31

SP - 125

EP - 133

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -